Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.

Endocrine
Yutaka MoriNaoko Tajima

Abstract

To investigate the relationship between insulin resistance, postprandial hyperglycemia, postprandial hyperlipidemia, and oxidative stress in type 2 diabetes, changes in postprandial glucose, triglyceride, and nitrotyrosine levels vs baseline after diet loading were examined in type 2 diabetic patients given pioglitazone (PG) or glibenclamide (GB). Twenty-four outpatients with type 2 diabetes treated with oral PG for 6 mo (BMI, 26.3 +/- 0.9; HbA1c, 8.2 +/- 0.2%) and 10 type 2 diabetic patients treated with GB (BMI, 27.4 +/- 1.6; HbA1c, 8.1 +/- 0.2%) at our institutions were compared. These patients were given meal tolerance tests (MTT; each consisting of energy 400 kcal, protein 8.7 g, fat 22.4 g, carbohydrate 41 g) before and 6 mo after administration of either agent. PG produced a significant decrease in FPG, HbA1c, HOMA-R, and TG levels in the subjects compared to baseline. In contrast, GB significantly decreased FPG and HbA1c levels, while not affecting HOMA-R and TG values. While PG produced a significant increase in LPL, HDL-cholesterol, and adiponectin levels, GB did not affect these values. At MTT 6 mo after PG administration, insulin levels before and 4 h after MTT, free fatty acid (FFA) levels 1, 2, and 4 h after MTT, ...Continue Reading

Citations

May 18, 2010·Diabetes Technology & Therapeutics·Giuseppe Derosa, Pamela Maffioli
May 17, 2011·Diabetes, Obesity & Metabolism·A Chaudhuri, P Dandona
Jul 28, 2012·International Journal of Molecular Sciences·Kiyoshi KikuchiEiichiro Tanaka
May 15, 2010·Journal of Atherosclerosis and Thrombosis·Atsuhito SaikiKohji Shirai
Apr 18, 2009·Southern Medical Journal·David S H Bell
Jun 28, 2011·Primary Care Diabetes·Dana E KingCharles J Everett
Sep 23, 2008·Metabolism: Clinical and Experimental·Shinji MakitaMotoyuki Nakamura
Nov 9, 2007·Diabetes/metabolism Research and Reviews·Antonio Ceriello
Jul 9, 2013·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Makoto OharaKyoichi Mizuno
Jul 3, 2013·Journal of Diabetes and Its Complications·Cyrus V Desouza
Oct 13, 2012·Experimental and Therapeutic Medicine·Kiyoshi KikuchiEiichiro Tanaka
Jan 26, 2011·Expert Opinion on Therapeutic Targets·Niki KatsikiDimitrios Karamitsos
Jul 1, 2012·Expert Review of Endocrinology & Metabolism·Ali A RizviManfredi Rizzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.